Russia and Eastern Europe is one of the most attractive regions to conduct clinical trials. There are several advantages to place clinical trials in this area:
- Population size, providing access to a large potential pool of mostly treatment naïve clinical trial subjects:
Russia 142.2 million Ukraine 46.6 million Bulgaria 7.7 million Lithuania 3.4 million Latvia 2.3 million Estonia 1.3 million Belarus 10 million Total 213.5 million - Centralized healthcare system with the developed referral network and a number of private practices. As a result - few sites needed to get a large number of patients
- Good selection of high-quality investigational sites
- ICH-GCP compliance principles incorporated into legislation
- High recruitment rates with low drop-out rates:
Patient recruitment rates in the region is up to 10 times higher than in US and EU
- Savings in costs:
Average cost per patient in Eastern Europe is 28% lower than in Western Europe and 47% than in the UK
Possibility to reduce clinical trial expenditure by using local CROs and labs - High level of qualification of investigators for conducting clinical trials. As a result – high quality clinical trial data
